Bayer US head says FDA chief reassured pharma executives of timely reviews
Written by Emily J. Thompson, Senior Investment Analyst
Updated: May 15 2025
0mins
Should l Buy ?
Source: Yahoo Finance
FDA Assurance: Bayer's COO, Sebastian Guth, expressed confidence that the FDA will meet its drug review targets despite recent job cuts, based on reassurances from FDA Commissioner Marty Makary during a meeting with industry executives.
Bayer's Performance: Bayer reported strong first-quarter sales growth in the U.S., particularly from its prostate cancer drug Nubeqa and kidney treatment Kerendia, contributing to significant revenue increases.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
